Project Grant 2427896
Award Date
5/1/25
Completion Date
4/30/27
Dollars Obligated
$250K
Federal Grant Program
47.041
Assistance Type
Project Grant
Place of Performance
Norfolk, VA 23529, USA
Similar Awards
This National Science Foundation (NSF) Engineering Program Project Grant, awarded to the University of South Florida (USF), aims to gain a fundamental understanding of the parameters of chimeric antigen receptors (CARs) that tune T cell responses, and to characterize how these parameters affect CAR engineered T cell function and fate. The $501,979 award, effective February 1, 2024 through January 31, 2029, will combine protein engineering, cell biology, and omics experiments to survey motif...
This National Science Foundation (NSF) Engineering Program (CFDA 47.041) project grant, awarded to Duke University, aims to decode how single-cell phenotypic heterogeneity arises and can be precisely controlled in T cells, which are critical for cancer immunotherapy. The $574,808 award, effective May 1, 2025 through April 30, 2030, will leverage cutting-edge technologies like spatial proteomic multiplexed imaging, in vitro cell tracking, and engineered biomaterial artificial antigen-presenting...
This Project Grant award from the National Science Foundation (NSF) under its Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $275,000 to Tectaria Bio LLC to engineer cell lines with activated proteasomes for increased biomanufacturing efficiency. The project aims to test the feasibility and application of a novel technology to significantly increase the protein production capabilities of cell lines used in the manufacture of biologics, gene therapies, and vaccines....
This $508,785 federal Project Grant award from the National Science Foundation's (NSF) Engineering program (CFDA 47.041) supports research at Columbia University to investigate how the chemical composition and mechanical properties of biomaterials can be optimized to improve the production and function of T cells for use in cancer immunotherapy. The project aims to gain fundamental knowledge on how nutrient transport, particularly oxygen availability, within these biomaterials affects T cell...
This Cooperative Agreement award from the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships program) provides $1,250,000.00 in funding to Rattan Life Science Inc., a small disadvantaged business, to develop a novel platform technology for scalable production of high-quality, tumor-targeted induced naïve T cells for off-the-shelf cancer immunotherapies. The project aims to demonstrate the in vivo anti-tumor efficacy of these induced naïve T cells against...
This National Science Foundation (NSF) Engineering Program (CFDA 47.041) Project Grant award of $600,000 to Dartmouth College aims to develop methodologies for efficiently manufacturing mature human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) to accelerate drug development and cardiac disease modeling. The project will employ biochip design, machine learning, developmental biology, and tissue engineering approaches to enhance the structural and functional maturity of...
This Project Grant award from the National Science Foundation (NSF) Engineering Program (CFDA 47.041) aims to develop scalable manufacturing processes for engineered extracellular vesicles (EVs) that can serve as targeted drug delivery vehicles. The $2.55M grant to Vanderbilt University, awarded on January 1, 2024, will fund research to harness cellular processes for optimizing EV production, cargo loading, and cellular uptake. The long-term goal is to establish a biomanufacturing platform for...
This Project Grant from the National Science Foundation's Division of Chemical, Bioengineering, Environmental, and Transport Systems provides $500,000 to the Regents of the University of California at Riverside for research on rapid biomanufacturing of mRNA vaccines in plant chloroplasts. The award period is from January 1, 2022 to December 31, 2023. The research is funded under the NSF Directorate for Engineering's 47.041 CFDA program, which aims to improve quality of life and economic strength...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $274,991 to Saber Therapeutics, Inc. will support the development of a new approach to deliver cancer-killing proteins specifically to acute myeloid leukemia (AML) cells while sparing healthy cells. The project aims to engineer natural killer (NK) cells with targeted protein degraders (TPDs) against three common AML driver proteins. The resulting NK-TPD cells will be tested for...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award to Genexgen Inc., a small disadvantaged business, is providing $274,763 to develop an mRNA-based tolerogenic vaccine to address immune response challenges in viral-based gene therapies. The proposed solution aims to train the immune system to ignore antigens expressed in gene therapy treatments, enabling higher and more persistent therapeutic protein expression. This could...